Last updated: February 13, 2026
What is NDC 65862-0670 and its current status?
NDC 65862-0670 corresponds to Libtayo (cemiplimab), marketed by Regeneron Pharmaceuticals. Approved by the FDA for the treatment of cutaneous squamous cell carcinoma (CSCC), it also has indications including basal cell carcinoma and non-small cell lung cancer.
Libtayo was first approved in September 2018. Its indications have expanded, increasing market coverage. It has a competitive landscape primarily involving other PD-1/PD-L1 inhibitors, such as Keytruda (pembrolizumab) and Opdivo (nivolumab).
What is the current market size for Libtayo (cemiplimab)?
Market revenue for Libtayo in the US reached approximately $600 million in 2022. The global market size is estimated at $1.2 billion for 2022, with projections indicating steady growth due to approval expansion.
Market drivers:
- Approval for additional indications including basal cell carcinoma (approved in July 2022).
- Rising incidence of skin cancers worldwide.
- Shift toward immunotherapy solutions over traditional therapies.
Market barriers:
- High treatment costs.
- Competition from established PD-1/PD-L1 drugs.
- Reimbursement hurdles in some regions.
How does Libtayo compare within the immunotherapy market?
| Drug |
Approved Indications |
2022 US Sales |
Price per Dose (USD) |
Dosing Schedule |
Market Share (2022) |
| Libtayo |
CSCC, BCC (since 2022), NSCLC, other |
~$600M |
~$7,400 (per 350 mg dose) |
350 mg every 3 weeks |
~15-20% |
| Keytruda |
Melanoma, NSCLC, others |
~$8.0B |
~$10,000 (per 200 mg dose) |
200 mg every 3 weeks |
50-55% |
| Opdivo |
Melanoma, NSCLC, RCC, others |
~$7.7B |
~$9,200 (per 240 mg dose) |
240 mg every 2 weeks |
40-45% |
Libtayo's share remains modest due to later market entry but gains ground with second-line treatment approval in specific indications.
What are the price projections for Libtayo?
Current pricing trends:
- The wholesale acquisition cost (WAC) for Libtayo is approximately $7,400 for a 350 mg dose.
- The annual treatment cost for a typical patient ranges from $70,000 to $100,000 depending on dosing and indication.
Forecasted pricing adjustments (2024-2028):
- Price stabilization or slight decreases are expected absent new patent expirations due to competition.
- Potential discounts or biosimilar entry could reduce prices by 10-15%, similar to trends observed with other immunotherapies.
- Reimbursement policies in major markets could influence net price, especially if payers negotiate significant discounts.
Market expansion impact:
- As additional indications are approved, total patient population increases, potentially offsetting price erosion.
- Volume growth expected to stabilize at a CAGR of 8-10% for global sales through 2028.
What are the risks for price and market growth?
- Patent expiration timelines remain uncertain, but exclusivity is likely until 2030-2025.
- Entry of biosimilars or generics could reduce prices.
- Competitive pressure from other immunotherapies may limit price increases.
- Regulatory delays or unmet safety concerns could hinder expansion.
Summary of key factors influencing market and pricing:
- Approval expansion into basal cell carcinoma boosts growth potential.
- Competitive landscape heavily influences price stabilization.
- Reimbursement strategies and payer negotiations impact net revenue.
- Biosimilars' development remains a key risk factor.
Key Takeaways
- Libtayo's market size was approximately $600 million in 2022, with steady growth expected.
- Pricing remains high, with an annual per-patient cost around $70,000 to $100,000.
- Market share is growing but limited by late entry relative to competitors.
- Price projections suggest stability or slight decline, barring new approvals or biosimilar entry.
- Long-term growth hinges on indication expansion and competitive positioning.
FAQs
1. When will biosimilars for Libtayo likely enter the market?
Biosimilar development timelines suggest entry could occur around 2025-2028, pending patent status and regulatory approval.
2. How does FDA approval of additional indications affect Libtayo’s market outlook?
New indications expand the eligible patient population, enhancing sales volume and potentially supporting higher prices initially.
3. What are the typical reimbursement challenges faced by Libtayo?
Reimbursement hurdles include insurance coverage limits, prior authorization requirements, and negotiated discounts with payers.
4. Are other regions seeing similar market dynamics?
Emerging markets have growing skin cancer incidences, but pricing and reimbursement policies vary, impacting regional sales growth.
5. What is the potential impact of new competitors on Libtayo's pricing?
Introduction of biosimilars or alternative therapies can pressure prices downward and reduce market share.
Sources
[1] FDA approval announcements and label updates.
[2] IQVIA sales data (2022).
[3] Market research reports (2022-2023).
[4] Pricing and reimbursement policy analyses (2022-2023).
[5] Competition landscape assessments from industry reports.
